Farmaceutica Remedia (BSE:RMAH) Beta: 0.2985 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:RMAH Farmaceutica Remedia SA BSE:RMAH
58 GF Score
Price lei0.87
GF Value lei0.79
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Farmaceutica Remedia Beta?

Farmaceutica Remedia BSE:RMAH +0.23% 58 Beta is 0.2985 as of Jul. 18, 2026. GuruFocus rates BSE:RMAH with a GF Score™ of 58/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-18), Farmaceutica Remedia's Beta is 0.2985.


Farmaceutica Remedia  (BSE:RMAH) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Farmaceutica Remedia Beta Related Terms


Farmaceutica Remedia Beta Historical Data

* Premium members only.

The historical data trend for Farmaceutica Remedia's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia Beta Chart

Farmaceutica Remedia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.04 0.30 0.26 0.04

Farmaceutica Remedia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.43 0.41 0.04 0.41

BSE:RMAH vs MCK, CAH, COR: Beta Comparison

For the Medical Distribution subindustry, Farmaceutica Remedia's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farmaceutica Remedia Beta vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Beta distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's Beta falls into.


BSE:RMAH
58GF Score
Farmaceutica Remedia SA BSE:RMAH
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2985 mean?
Farmaceutica Remedia (BSE:RMAH) has a Beta of 0.2985 as of Jul. 18, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Beta too high?
Farmaceutica Remedia's current Beta is 0.2985. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Beta compare to MCK and CAH?
Farmaceutica Remedia's Beta of 0.2985 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Beta is 0.2985. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Beta is 0.2985. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Beta is 0.2985 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued. The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79. GuruFocus considers Farmaceutica Remedia to be Fairly Valued.

Key valuation signals for BSE:RMAH:

  • Beta: 0.2985
  • GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Farmaceutica Remedia Business Description

Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score

Get the complete analysis for BSE:RMAH

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.87
Price
lei0.79
GF Value